TREATMENT WITH LUTEINIZING-HORMONE-RELEASING HORMONE ANTAGONIST SB-75 DECREASES LEVELS OF EPIDERMAL GROWTH-FACTOR RECEPTOR AND ITS MESSENGER-RNA IN OV-1063 HUMAN EPITHELIAL OVARIAN-CANCER XENOGRAFTS IN NUDE-MICE

  • Authors:
    • Y SHIRAHIGE
    • CB COOK
    • J PINSKI
    • G HALMOS
    • R NAIR
    • AV SCHALLY
  • View Affiliations

  • Published online on: November 1, 1994     https://doi.org/10.3892/ijo.5.5.1031
  • Pages: 1031-1035
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of this study was to investigate the effect of administration of LH-RH antagonist SB-75 and agonist [D-Trp(6)]LH-RH on receptors for epidermal growth factor (EGF) in OV-1063 human epithelial ovarian cancer. Female athymic nude mice bearing xenografts of OV-1063 human epithelial ovarian cancer were treated for 3 weeks with the modern LH-releasing hormone (LH-RH) antagonist [Ac-DNal(2)(1), D-Phe(4Cl)(2), D-Pal(3)(3), D-Cit(6), D-Ala(10)] LH-RH (SB-75, Cetrorelix), the agonist [D-Trp(6)]LH-RH, or bombesin/gastrin-releasing peptide antagonist RC-3095. SB-75 and [D-Trp(6)] LH-RH were injected s.c. at doses of 100 mu g/day, and RC-3095 was injected at a dose of 40 mu g/day. Tumor growth, as measured by percentage change in tumor volume, was significantly inhibited by the treatment with SB-75, but not by [D-Trp(6)] LH-RH or RC-3095. Treatment with SB-75 greatly decreased the levels of mRNA for EGF receptor and reduced the number of EGF binding sites on tumor membranes. Effects of SB-75 on EGF receptors might be related to inhibition of tumor growth. Our findings support the view that LH-RH antagonists such as SB-75 could be considered for possible hormonal therapy of epithelial ovarian cancer.

Related Articles

Journal Cover

November 1994
Volume 5 Issue 5

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
SHIRAHIGE Y, COOK C, PINSKI J, HALMOS G, NAIR R and SCHALLY A: TREATMENT WITH LUTEINIZING-HORMONE-RELEASING HORMONE ANTAGONIST SB-75 DECREASES LEVELS OF EPIDERMAL GROWTH-FACTOR RECEPTOR AND ITS MESSENGER-RNA IN OV-1063 HUMAN EPITHELIAL OVARIAN-CANCER XENOGRAFTS IN NUDE-MICE. Int J Oncol 5: 1031-1035, 1994.
APA
SHIRAHIGE, Y., COOK, C., PINSKI, J., HALMOS, G., NAIR, R., & SCHALLY, A. (1994). TREATMENT WITH LUTEINIZING-HORMONE-RELEASING HORMONE ANTAGONIST SB-75 DECREASES LEVELS OF EPIDERMAL GROWTH-FACTOR RECEPTOR AND ITS MESSENGER-RNA IN OV-1063 HUMAN EPITHELIAL OVARIAN-CANCER XENOGRAFTS IN NUDE-MICE. International Journal of Oncology, 5, 1031-1035. https://doi.org/10.3892/ijo.5.5.1031
MLA
SHIRAHIGE, Y., COOK, C., PINSKI, J., HALMOS, G., NAIR, R., SCHALLY, A."TREATMENT WITH LUTEINIZING-HORMONE-RELEASING HORMONE ANTAGONIST SB-75 DECREASES LEVELS OF EPIDERMAL GROWTH-FACTOR RECEPTOR AND ITS MESSENGER-RNA IN OV-1063 HUMAN EPITHELIAL OVARIAN-CANCER XENOGRAFTS IN NUDE-MICE". International Journal of Oncology 5.5 (1994): 1031-1035.
Chicago
SHIRAHIGE, Y., COOK, C., PINSKI, J., HALMOS, G., NAIR, R., SCHALLY, A."TREATMENT WITH LUTEINIZING-HORMONE-RELEASING HORMONE ANTAGONIST SB-75 DECREASES LEVELS OF EPIDERMAL GROWTH-FACTOR RECEPTOR AND ITS MESSENGER-RNA IN OV-1063 HUMAN EPITHELIAL OVARIAN-CANCER XENOGRAFTS IN NUDE-MICE". International Journal of Oncology 5, no. 5 (1994): 1031-1035. https://doi.org/10.3892/ijo.5.5.1031